Please assess the completion status of the following clinical trial:

Trial Title: Study of Immunotoxin, MR1-1

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Residual, progressive, or recurrent supratentorial malignant brain tumor based on imaging studies with measurable disease (\>0.5cm).~* Patient will have completed some form of radiation therapy prior to toxin treatment.~* Karnofsky Performance score \>70.~* The presence of the target antigen, EGFRvIII, must be identified on tumor tissue by immunohistochemistry.~* Platelet count \> 100 x 109/L; PTT and PT \< 120% of normal range.~* Creatinine \< 120% of normal range.~* Total bilirubin, SGOT, SGPT,alkaline phosphatase \< 300% of normal range.~Exclusion Criteria:~* Patients who are pregnant, breast-feeding, or unwilling to practice an effective method of birth control.~* Patients with known potentially anaphylactic allergic reactions to iodine or gadolinium-DTPA.~* Patients who cannot undergo MRI due to obesity or to having certain metal in their bodies (specifically pacemakers, infusion pumps, metal aneurysm clips, metal prostheses, joints, rods or plates).~* Patients that have not recovered from the toxic effects of prior chemotherapy and/or radiation therapy.~* Patients with an impending, life-threatening cerebral herniation syndrome.~* Patients with subependymal or CSF disease.~* Patients who are under the age of 18 years.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MR1-1 (Type: EXPERIMENTAL): All subjects are enrolled onto this arm. All subjects will receive MR1-1.

Based on this trial design, predict the completion outcome and termination type (if applicable).